Financial Performance - Bolt Biotherapeutics reported a quarterly loss of $0.29 per share, better than the Zacks Consensus Estimate of a loss of $0.34, and compared to a loss of $0.28 per share a year ago, indicating an earnings surprise of 14.71% [1] - The company posted revenues of $1.22 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 19.45%, but down from $5.27 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates just once and topped consensus revenue estimates three times [2] Stock Performance - Since the beginning of the year, Bolt Biotherapeutics shares have declined by approximately 33.1%, while the S&P 500 has decreased by 3.8% [3] - The current Zacks Rank for Bolt Biotherapeutics is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $0.99 million, and for the current fiscal year, it is -$1.27 on revenues of $3.79 million [7] - The estimate revisions trend for Bolt Biotherapeutics is mixed, and future stock movements will depend on management's commentary during the earnings call [3][4] Industry Context - The Medical - Biomedical and Genetics industry, to which Bolt Biotherapeutics belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates